106 related articles for article (PubMed ID: 17595216)
1. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.
Herling AW; Gossel M; Haschke G; Stengelin S; Kuhlmann J; Müller G; Schmoll D; Kramer W
Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E826-32. PubMed ID: 17595216
[TBL] [Abstract][Full Text] [Related]
2. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
[TBL] [Abstract][Full Text] [Related]
3. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.
Herling AW; Kilp S; Elvert R; Haschke G; Kramer W
Endocrinology; 2008 May; 149(5):2557-66. PubMed ID: 18276749
[TBL] [Abstract][Full Text] [Related]
4. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors.
Vijayakumar RS; Lin Y; Shia KS; Yeh YN; Hsieh WP; Hsiao WC; Chang CP; Chao YS; Hung MS
Int J Obes (Lond); 2012 Jul; 36(7):999-1006. PubMed ID: 21894162
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
Zuurman L; Roy C; Schoemaker RC; Amatsaleh A; Guimaeres L; Pinquier JL; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Mar; 24(3):363-71. PubMed ID: 18801827
[TBL] [Abstract][Full Text] [Related]
6. Excessive energy intake does not modify fed-state tissue protein synthesis rates in adult rats.
Adéchian S; Giardina S; Rémond D; Papet I; Buonocore D; Gaudichon C; Dardevet D; Marzatico F; Mosoni L
Obesity (Silver Spring); 2009 Jul; 17(7):1348-55. PubMed ID: 19247270
[TBL] [Abstract][Full Text] [Related]
7. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats.
Lamota L; Bermudez-Silva FJ; Marco EM; Llorente R; Gallego A; Rodríguez de Fonseca F; Viveros MP
Neuropharmacology; 2008 Jan; 54(1):194-205. PubMed ID: 17720206
[TBL] [Abstract][Full Text] [Related]
8. Effects of sucrose, glucose and fructose on peripheral and central appetite signals.
Lindqvist A; Baelemans A; Erlanson-Albertsson C
Regul Pept; 2008 Oct; 150(1-3):26-32. PubMed ID: 18627777
[TBL] [Abstract][Full Text] [Related]
9. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Black MD; Stevens RJ; Rogacki N; Featherstone RE; Senyah Y; Giardino O; Borowsky B; Stemmelin J; Cohen C; Pichat P; Arad M; Barak S; De Levie A; Weiner I; Griebel G; Varty GB
Psychopharmacology (Berl); 2011 May; 215(1):149-63. PubMed ID: 21181124
[TBL] [Abstract][Full Text] [Related]
10. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?
Kunos G
Am J Med; 2007 Sep; 120(9 Suppl 1):S18-24; discussion S24. PubMed ID: 17720356
[TBL] [Abstract][Full Text] [Related]
11. The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats.
Ortmann S; Kampe J; Gossel M; Bickel M; Geisen K; Jähne G; Lang HJ; Klaus S
Obes Res; 2004 Aug; 12(8):1290-7. PubMed ID: 15340112
[TBL] [Abstract][Full Text] [Related]
12. Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity.
Fam BC; Morris MJ; Hansen MJ; Kebede M; Andrikopoulos S; Proietto J; Thorburn AW
Diabetes Obes Metab; 2007 Nov; 9(6):840-52. PubMed ID: 17924866
[TBL] [Abstract][Full Text] [Related]
13. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
15. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
16. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
Kunz I; Meier MK; Bourson A; Fisseha M; Schilling W
Int J Obes (Lond); 2008 May; 32(5):863-70. PubMed ID: 18253160
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
18. Energy expenditure and substrate oxidation rates of obese rats during a 12-day treatment with dexfenfluramine.
Boschmann M; Aust L; Frenz U; Noack R
Ann Nutr Metab; 1996; 40(1):10-23. PubMed ID: 8722302
[TBL] [Abstract][Full Text] [Related]
19. Sequential responses to high-fat and high-calorie feeding in an obese mouse model.
Chan MY; Zhao Y; Heng CK
Obesity (Silver Spring); 2008 May; 16(5):972-8. PubMed ID: 18292748
[TBL] [Abstract][Full Text] [Related]
20. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
